Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 7/20 | 0.61 |
| ▸ | BRAF | P15056 | 10/20 | 0.42 |
| ▸ | KDR | P35968 | 11/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29788821 | 1.00 | GCK (0.61) | GCKBRAFKDR | |
| SCHEMBL29083253 | 0.88 | CSF1R (0.46) | GCKBRAFKDR | |
| SCHEMBL29083236 | 0.85 | GCK (0.45) | GCKBRAFKDR | |
| SCHEMBL29083254 | 0.85 | GCK (0.44) | GCKBRAFKDR | |
| SCHEMBL29083252 | 0.85 | GCK (0.43) | GCKBRAFKDR | |
| SCHEMBL2550993 | 0.85 | GCK (0.61) | GCKBRAFKDR | |
| SCHEMBL29083265 | 0.84 | KDR (0.55) | BRAFKDR | |
| SCHEMBL2554803 | 0.84 | GCK (0.65) | GCK | |
| SCHEMBL13504234 | 0.83 | KDR (0.47) | GCKKDR | |
| SCHEMBL2551479 | 0.82 | GCK (0.56) | GCKBRAFKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114907339-B | 4- (4-aminophenoxy) pyridin-2-amine derivatives and use thereof | 成都奥睿药业有限公司 | 2023-07-14 | — | — | CN | disclosed |
| CN-114907339-A | 4- (4-aminophenoxy) pyridin-2-amine derivatives and uses thereof | 成都奥睿药业有限公司 | 2022-08-16 | — | — | CN | disclosed |
| EP-2556068-B1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2019-01-23 | — | — | EP | disclosed |
| US-9024041-B2 | P38 MAP kinase inhibitors | RESPIVERT LTD. (GB) | 2015-05-05 | — | — | US | disclosed |
| US-20130040962-A1 | P38 MAP Kinase Inhibitors | RESPIVERT LTD (GB) | 2013-02-14 | — | — | US | disclosed |
| EP-2556068-A1 | P38 MAP KINASE INHIBITORS | Respivert Limited (GB) | 2013-02-13 | — | — | EP | disclosed |
| WO-2011124930-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2011-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040962-A1 | P38 MAP Kinase Inhibitors | MAPK15, MAPK1, MAP3K15 | GCK 1335/4885BRAF 115/4885KDR 3873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.